Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Retained Earnings (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Retained Earnings for 10 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 200.0% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 200.0% year-over-year, with the annual reading at $1.0 million for FY2025, 200.0% up from the prior year.
  • Retained Earnings for Q4 2025 was $1.0 million at Ultragenyx Pharmaceutical, up from -$4.4 billion in the prior quarter.
  • The five-year high for Retained Earnings was $1.0 million in Q4 2025, with the low at -$4.4 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$1.9 billion, with a median of -$2.0 billion recorded in 2021.
  • The sharpest move saw Retained Earnings crashed 170285.87% in 2024, then surged 200.0% in 2025.
  • Over 5 years, Retained Earnings stood at -$2.1 billion in 2021, then crashed by 34.12% to -$2.8 billion in 2022, then dropped by 21.81% to -$3.4 billion in 2023, then soared by 99.97% to -$1.0 million in 2024, then soared by 200.0% to $1.0 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $1.0 million, -$4.4 billion, and -$268000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.